Conflict of interest as seen from a researcher’s perspective
- 40 Downloads
The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research.
Keywordsconflict of interest academic research drug development and research clinical trial design
Unable to display preview. Download preview PDF.
- 1.Pharma2005: An industrial revolution in R&D. New York, NY: PriceWaterhouseCoopers; 1998. Available at http://www.pwcconsulting.com/us/pwccons.nsf/viewwebpages/PharmaPubSeries Accessibility verified May 2002.Google Scholar
- 2.The new era of lifestyle drugs. BusinessWeek May 11, 1998. Available at http://www.businessweek.com/1998/19/topstory.htm. Accessibility verified May 2002.Google Scholar
- 3.Garattini S. (1997) Are me-too drugs justified? J Nephrol. 10: 283–94.Google Scholar
- 7.Perna A., Gotti E., de Bernardis E., Perico N., Remuzzi G. (1996) A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol. 7: 786–91.Google Scholar
- 13.Kurtzman N.A. (2001) Drug companies should not have the final say in the design of clinical trials. Am J Kidney Dis 38: 1113–4.Google Scholar
- 15.About the 1999 WHO/ISH guidelines for the management of hypertension. Available at http://www.uib.no/isf/letter Accessibility verified May 2002.Google Scholar
- 17.Quick J. (2001) Maintaining the integrity of the clinical evidence base. Bulletin of the WHO 79: 1093.Google Scholar